Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Azacitidine in the management of patients with myelodysplastic syndromes.

    ... Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoeitic disorders characterized ... of tumor suppressor genes in high-risk MDS and secondary leukemias. Hence, the role of irreversible DNA methlytransferase ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia.

    ... to the pathogenesis of myelodysplastic syndromes (MDS) and may trigger disease-progression to secondary acute myeloid leukemia (AML). Expression of apoptosis-mediators FAS ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Diagnosis of myelodysplastic syndromes in cytopenic patients

    ... the bone marrow (BM), a diagnosis of cytopenia secondary to an infiltrative BM process or acute leukemia can be readily ... to establish a diagnosis of myelodysplastic syndrome (MDS). In this article, the practical approaches for establishing or excluding a ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure

    ... (AZA) failure in higher-risk myelodysplastic syndromes (MDS) is poor and new treatment options are needed. Erlotinib, an oral ... or 150mg/day (n=25) of Erlotinib orally after primary or secondary resistance to AZA treatment. Eighteen MDS and 12 AML patients were ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes

    ... studies suggest that most cases of myelodysplastic syndrome (MDS) are clonally heterogeneous, with a founding clone and multiple ... 94 candidate genes in a cohort of 157 patients with MDS or secondary acute myeloid leukemia (sAML). This included 150 cases with samples ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update

    ... Patients with myelodysplastic syndromes (MDS), especially those with high-risk disease, other comorbidities, or of ... System (IPSS) intermediate-1 to high risk patients, in secondary acute myeloid leukemia (AML) arising from MDS, and in MDS with ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

    ... of somatic mutations in myelodysplastic syndromes (MDS), the clinical relevance of variant allele frequency (VAF) for the ... genes in our training set of 219 patients with MDS or secondary acute myeloid leukemia with findings confirmed in a validation ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes

    ... Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders that often progress to chemotherapy -resistant secondary acute myeloid leukemia (sAML). We used whole-genome sequencing to ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms

    ... as a discovery tool in myelodysplastic syndromes (MDS) has led to the identification of a large number of novel mutations. ... and identification of a subset of ancestral and secondary molecular lesions. Chromosomal gains and losses have been ... phenocopy. In addition to the search for somatic defects in MDS, similar discovery studies have been also performed to identify germ line ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes

    ... multiple myeloma (MM) and myelodysplastic syndromes (MDS). Long-term continuous treatment with lenalidomide beyond first response ... on treatment and achieve optimal efficacy, is discussed. Secondary primary malignancies in MM and progression to acute myeloid leukemia ...

    Research Article last updated 07/20/2018 - 5:14pm.